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A PROSPECTIVE STUDYSte´phane Moutereau, Pascal Eschwege, Zahi Aboujeili, Ste´phane
Droupy, Richard Douard, Jean-Luc Gala, Marc Conti, Philippe
Manivet, Sylvain Loric. INSERM EMI0337 and Clinical Biochemistry
and Genetics Department, APHP Mondor University Hospital, Cre´teil,
France.
Background: During the natural history of prostate cancer,
bloodstream prostate cell dissemination occurs, even in clinically
localised prostate cancer patients. Additionally, prostate manipu-
lation during radical prostatectomy induces hematogenous pros-
tatic cell dissemination. Both may play an adverse role on the
natural course of the disease. Blood-borne circulating prostate
cell detection might be helpful to better classify patients and pre-
dict recurrence.
Methods: To evaluate cancer-cell seeding impact upon patient
recurrence free survival, 111 prostate cancer patients were pro-
spectively enrolled and followed up. Prostate cell spread was
assessed by PSMA-based RT-PCR. Positive recurrence was defined
by two consecutive serum PSA values P0.2 ng/L.
Results: Forty-one patients presented blood prostate cell shed-
ding preoperatively and intraoperatively (group I). Of the 70 pre-
operatively negative patients, 38 (54%) remained negative (group
II) and 32 (46%) became intraoperatively positive (group III). Med-
ian biological and clinical recurrence-free-time was far shorter in
group I (36.2 months, p < 0.0001) than in group II (69.6 months) but
did not significantly differ in groups II and III (69.6 months versus
65.0).
Conclusions: Such 5-year follow-up data show that preoperative
circulating prostate cells are an independent prognosis factor of
recurrence. Moreover, tumor handling induces cancer-cell seed-
ing but this surgical blood dissemination does not accelerate can-
cer evolution.
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FROM PATIENTS WITH ESOPHAGEAL CANCER DECREASE
SIGNIFICANTLY FOLLOWING SURGICAL RESECTION AND
ARE INFLUENCED BY NEOADJUVANT CHEMORADIATIONA.-C. Hoffmann, U. Warnecke-Eberz, K. Prenzel, J. Brabender,
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Schneider. Department of Visceral and Vascular Surgery, University
of Cologne, Joseph-Stelzmann-Strasse 9, 50931 Cologne, Germany.
Background: Survivin is an inhibitor of apoptosis and specifically
expressed in several human cancers. The purpose of this study
was to evaluate if there is a difference in the level of survivin
mRNA expression between different histological types and stages
of esophageal cancer. Furthermore we evaluated if a potential
postresectional decrease in survivin mRNA expression might be
used to verify complete surgical resection and if neoadjuvant
chemoradiation would influence these results.Methods: Blood samples were obtained from 47 patients who
were scheduled for surgical resection of an esophageal carci-
noma. 21 (44.7%) patients had squamous cell carcinomas and 26
(55.3%) adenocarcinomas. In 21 (44.7%) patients neoadjuvant
chemoradiation was perforemd for locally advanced disease.
Whole blood was drawn one day preoperatively and 10 days post
resection in all patients. The tumor cells were enriched from
whole blood by density gradient centrifugation (OncoQuick,
Hexal, Frickenhausen) and total cellular RNA was extracted.
Direct quantitative real-time reverse transcriptase PCR (RT-PCR,
TaqManTM) assays were performed in triplicates to determine sur-
vivin mRNA expression levels.
Results: Survivin mRNA expression in peripheral blood was
detected in 35/47 patients (74.5%). There were no significant dif-
ferences in preoperative mRNA levels between squamous cell car-
cinomas and adenocarcinomas. Postoperative survivin levels
were significantly lower than preoperative levels in 41.2% of
resected patients. Postoperative levels were lower than preopera-
tive levels in 52.9% of patients with adenocarcinomas and 29.4%
of patients with squamous cell carcinomas. Patients who received
neoadjuvant chemoradiation had significantly lower survivin
mRNA levels postoperatively in 66.7% compared to 27.3% of
patients following primary resection (Wilcoxon test: p < 0,027).
In patients receiving neoadjuvant chemoradiation postoperative
mRNA expression levdels were detected at 83.3% of patients with
adenocarcinomas compared to only 36.4% with squamous cell
cancer.
Conclusions: Our results demonstrate that direct real-time
quantitative RT-PCR analysis of survivin mRNA expression with-
out prior nested PCR is technically feasible and reliable following
tumor cell enrichment from whole blood samples in patients with
esophageal cancer. Survivin levels were significantly reduced fol-
lowing surgical resections and might become a molecular marker
for completeness of resection (molecular R0 marker). Survivin
levels particularly decreased in adenocarcinomas following neo-
adjuvant chemoradiation and surgical resection.
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P32. CD133 POSITIVE ‘‘CANCER STEM CELLS’’ IN GLIOMAS OF
DIFFERENT GRADES
N. Thon, S. Grau, K. Damianoff, O. Schnell, J.C. Tonn, R.
Goldbrunner. Neurochirurgische Klinik der Universita¨t Mu¨nchen,
Germany.
Background: Within glioblastoma multiforme (GBM) specimens,
a subpopulation of CD133 positive cells with ability for self
renewal and tumor generation could be isolated suggesting the
presence of ‘‘cancer stem cells’’ (CSC) in GBM. Aim of this study
was (i) to assess the presence of CD133+ cells in gliomas grade
II, III and IV and (ii) to investigate the differentiation potential of
these cells.
Methods: Samples of WHO II (10), WHO III (10) and WHO IV (10)
gliomas were investigated immunohistochemically using the
antibody AC133/1+2, which binds to two different epitopes of
CD133, and Musashi-1, an established stem cell marker. Addition-
ally, CD133 expression was assessed by ELISA. CD133+ cells were
